Subscribe To

Price Alert Latest News Economic Calendar News

COPHF / Creso Pharma psychedelics subsidiary Halucenex lodges CTA to test efficacy of psilocybin on treatment-resistant PTSD

Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF) psychedelics subsidiary Halucenex Life Sciences Inc has lodged a Clinical Trial Authorisation (CTA) with Health Canada for a planned phase II clinical trial to test the efficacy of psilocybin on treatment-resistant Post Traumatic Stress Disorder (PTSD). The proposed phase II clinical trial is designed to be a single-arm, open-lab trial that will ultimately determine the feasibility of future trials of psilocybin in this indication. Read More

Demo Live Account See Partner Details

Content Topics

Creso

Pharma

Psychedelics

Subsidiary

Halucenex

Lodges

Test

Efficacy

Psilocybin

Treatment resistant

Stock

COPHF

Posted: Jan 24 2022, 21:40

Author Name: Proactive Investors

COPHF News

By Proactive Investors
July 18, 2022

Creso Pharma psychedelics subsidiary Halucenex Life Sciences broadens scope ahead of Phase 2 clinical trials

Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF) (Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF), Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF)) subsidiary Halucenex Life

By Proactive Investors
February 7, 2022

Creso Pharma subsidiary on official list to provide psilocybin to Canadian doctors

Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF)'s wholly-owned, Canadian-based psychedelics subsidiary Halucenex Life Sciences Inc. has been included on a li

By Proactive Investors
February 7, 2022

Creso Pharma subsidiary on official list to provide psilocybin to Canadian doctors

Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF)'s wholly-owned, Canadian-based psychedelics subsidiary Halucenex Life Sciences Inc. has been included on a li

By Proactive Investors
February 7, 2022

Creso Pharma subsidiary on official list to provide psilocybin to Canadian doctors

Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF)'s wholly-owned, Canadian-based psychedelics subsidiary Halucenex Life Sciences Inc. has been included on a li

By Benzinga
February 4, 2022

Australian Creso Pharma To Enter US CBD Market Via $21M Acquisition Of Sierra Sage Herbs

Cannabis company Creso Pharma Limited (ASX: CPH) (OTC: COPHF) (FRA:1X8) is entering the US CBD market, following a purchase agreement to acquire Color

By Benzinga
February 4, 2022

Australian Creso Pharma To Enter US CBD Market Via $21M Acquisition Of Sierra Sage Herbs

Cannabis company Creso Pharma Limited (ASX: CPH) (OTC: COPHF) (FRA:1X8) is entering the US CBD market, following a purchase agreement to acquire Color

By Benzinga
February 4, 2022

Australian Creso Pharma To Enter US CBD Market Via $21M Acquisition Of Sierra Sage Herbs

Cannabis company Creso Pharma Limited (ASX: CPH) (OTC: COPHF) (FRA:1X8) is entering the US CBD market, following a purchase agreement to acquire Color

By Proactive Investors
February 2, 2022

Creso Pharma pushes into US CBD market with revenue-generating acquisition

Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF) has entered the US CBD market. The company has executed a Membership Interest Purchase Agreement to acquire Co

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Subscribe To

Live Trading Account

Open live account in few minutes with just 10$

COPHF / Creso Pharma psychedelics subsidiary Halucenex lodges CTA to test efficacy of psilocybin on treatment-resistant PTSD

Creso

Pharma

Psychedelics

Subsidiary

Halucenex

Lodges

Test

Efficacy

Psilocybin

Treatment resistant

Stock

COPHF

COPHF News

Creso Pharma psychedelics subsidiary Halucenex Life Sciences broadens scope ahead of Phase 2 clinical trials

Creso Pharma subsidiary on official list to provide psilocybin to Canadian doctors

Creso Pharma subsidiary on official list to provide psilocybin to Canadian doctors

Creso Pharma subsidiary on official list to provide psilocybin to Canadian doctors

Australian Creso Pharma To Enter US CBD Market Via $21M Acquisition Of Sierra Sage Herbs

Australian Creso Pharma To Enter US CBD Market Via $21M Acquisition Of Sierra Sage Herbs

Australian Creso Pharma To Enter US CBD Market Via $21M Acquisition Of Sierra Sage Herbs

Creso Pharma pushes into US CBD market with revenue-generating acquisition